Non-Hodgkin’s lymphoma (NHL) treatment in elderly populations often requires distinct approaches compared to younger patients due to differences in physiology, comorbidities, and tolerance to therapy. While the core principles of treating NHL remain the same—aiming to eradicate or control malignant…
Non-Hodgkin’s lymphoma (NHL) is a complex group of blood cancers that affect the lymphatic system, and its impact varies widely across the globe. Research into NHL increasingly focuses on understanding and addressing these global disparities, which arise from differences in…
The concept of chemotherapy-free regimens for non-Hodgkin’s lymphoma (NHL) has been gaining significant attention in recent years. This shift towards innovative treatments is driven by the desire to reduce the harsh side effects associated with traditional chemotherapy, while maintaining or…
Clinical registries play a crucial and multifaceted role in non-Hodgkin’s lymphoma (NHL) research by systematically collecting, organizing, and analyzing patient data over time. These registries serve as comprehensive databases that capture detailed information about patients’ diagnoses, treatments, outcomes, and disease…
Non-Hodgkin’s lymphoma (NHL) is a complex group of blood cancers that affect the lymphatic system, which is part of the immune system. Traditional treatments for NHL, such as chemotherapy, radiation, and immunotherapy, have improved patient outcomes over the years, but…
Researchers evaluate the **durability of immunotherapy in non-Hodgkin’s lymphoma (NHL)** by carefully measuring how long patients maintain a positive response after treatment and by analyzing various clinical, biological, and molecular factors that influence long-term outcomes. Durability refers to the length…
Positron Emission Tomography (PET) scans, especially when combined with computed tomography (CT) as PET/CT, have significantly improved the accuracy of staging in non-Hodgkin’s lymphoma (NHL). Staging is the process of determining the extent and spread of lymphoma in the body,…
New imaging techniques play a transformative role in non-Hodgkin’s lymphoma (NHL) research by enhancing the detection, monitoring, and understanding of the disease in ways that were previously impossible. These advances are reshaping how researchers and clinicians approach diagnosis, treatment planning,…
Non-Hodgkin’s lymphoma (NHL) survivors can develop treatment-related dementia, although this is a complex and not fully understood phenomenon. Treatment-related dementia refers to cognitive decline that arises as a consequence of cancer therapies rather than the cancer itself. In the case…
The survivability of cancer in the United States varies widely depending on the type of cancer, the stage at which it is diagnosed, and other factors such as age, race, and access to healthcare. Overall, cancer survival rates have improved…